Evidence for a defect in NADH: Ubiquinone oxidoreductase (Complex I) in Huntington’s disease

Neurology

Volumn 40, Issue 8, 1990, Pages 1231-1234

  Parker, William Davis ^a   Boyson, Sally J ^a   Luder, Anthony S ^a   Parks, Janice K ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OXIDOREDUCTASE; UBIQUINONE;

ARTICLE; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; MITOCHONDRION; PRIORITY JOURNAL; THROMBOCYTE;

BLOOD PLATELETS; ELECTRON TRANSPORT; FEMALE; HUMAN; HUNTINGTON DISEASE; MALE; MIDDLE AGE; MITOCHONDRIA; NAD(P)H DEHYDROGENASE (QUINONE); QUINONE REDUCTASES; REFERENCE VALUES; RISK FACTORS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0025087726     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/wnl.40.8.1231     Document Type: Article

References (19)

1. Huntington G. On chorea. Medical and Surgical Reporter 1872;26:317-321.
2. Folstein SE, Leigh J, Parhad IM, Folstein MF. The diagnosis of Huntington’s disease. Neurology 1986;36:1279-1283.
3. Gusella JF, Wexler NS, Conneally PM, et al. A polymorphic DNA marker genetically linked to Huntington’s disease. Nature 1983;306:234-238.
4. Parker WD, Oley C, Parks JK. Deficient NADH: coenzyme Q oxidoreductase activity in Leber’s hereditary optic atrophy. N Engl J Med 1989;320:1331-1333.
5. Wallace DC, Gurparkash S, Lott MT, et al. Mitochondrial DNA mutation associated with Leber’s hereditary optic atrophy. Science 1988;242:1427-1430.
6. Parker WD, Boyson SJ, Parks JK. Electron transport chain abnormalities in idiopathic Parkinson’s disease. Ann Neurol 1989;26:719-723.
7. Schapira AHV, Cooper JM, Dexter D, Jenner P, Clark JN, Mars- den CD. Mitochondrial complex I deficiency in Parkinson’s disease. Lancet 1989;1:1296.
8. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-980.
9. Ramsey RR, Singer TP. Energy dependent uptake of JV-methyl-4- phenylpyridinium, the neurotoxic metabolite of l-methyl-4-phe- nyl-l,2,3,6-tetrahydropyridine, by mitochondria. J Biol Chem 1986;261:7585-7587.
10. Parker WD, Frerman F, Haas R, Parks JK. Myxothiazol resistance in human mitochondria. Biochim Biophys Acta 1988;936:133-138.
11. Heron C, Smith S, Ragan CL An analysis of the polypeptide composition of bovine heart mitochondrial NADH-ubiquinone oxidoreductase by two-dimensional polyacrylamide-gel electrophoresis. Biochem J 1979;181:435-443.
12. Chomyn A, Mariottini P, Cleeter MWJ, et al. Six unidentified reading frames of human mitochondrial DNA encode components of the respiratory-chain NADH dehydrogenase. Nature 1985;314:592-597.
13. Chomyn A, Cleeter MWJ, Ragan CI, Riley M, Doolittle RF, Attardi G. URF6, last unidentified reading frame of human mtDNA codes for an NADH dehydrogenase subunit. Science 1986;234:614-618.
14. Giles RE, Blanc H, Cann HM, Wallace DC. Maternal inheritance of human mitochondrial DNA. Proc Natl Acad Sci USA 1980;77:6715-6719.
15. Coyle JT, Schwarcz R. Lesions of striatal neurones with kainic acid provides a model for Huntington’s chorea. Nature 1976;263:244-246.
16. Retz KC, Coyle JT. Effects of kainic acid on high-energy metabolites in the mouse striatum. J Neurochem 1982;38:196-203.
17. Wexler NS, Young AB, Tanzi RE, et al. Homozygotes for Huntington’s disease. Nature 1987;326:194-197.
18. White RAH, Akam ME. Contrabithorax mutations cause inappropriate expression of ultrabithorax products in Drosophila. Nature 1985;318:567-569.
19. Shoulson I, Fahn S. Huntington disease: clinical care and evaluation. Neurology 1979;29:1-3.